Our search criteria included the following terms: “osimertinib”, “resistance”, “non-small cell lung cancer”, “clinical trials”, “cell lines”, as well as keywords related to acquired mechanisms of resistance, including but not limited to “C797X”, “small-cell transformation”, “squamous cell transformation”, “MET amplification”, “HER2 amplification”, “HER2 mutation”, “RET fusions”, “BRAF mutations”, “BRAF amplification”, and “RAS mutations”. This evidence concerns the gene MET and non-small cell lung carcinoma.